Circulating Microparticles in Children With Sickle Cell Anemia in a Tertiary Center in Upper Egypt
| Autor: | Mohamd A Alblihed, Khaled Saad, Shereen M. Galal, Khalid I Elsayh, Asmaa M Zahran, Mostafa Embaby, Helal F Hetta, Yasser F. Abdel-Raheem, Mohamed Diab Aboul-Khair, Amira A. El-Houfey, Mervat A M Youssef, Shaban M. Sror |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Hemolytic anemia
Male medicine.medical_specialty lcsh:Diseases of the circulatory (Cardiovascular) system congenital hereditary and neonatal diseases and abnormalities Cell Disease Anemia Sickle Cell Gastroenterology hydroxyurea Flow cytometry Tertiary Care Centers children Cell-Derived Microparticles Internal medicine Medicine Humans Platelet In patient Child Thrombotic risk microparticles medicine.diagnostic_test business.industry Sickle cell disease Hematology General Medicine medicine.disease Flow Cytometry Sickle cell anemia medicine.anatomical_structure lcsh:RC666-701 Egypt Female Original Article business |
| Zdroj: | Clinical and Applied Thrombosis/Hemostasis Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019) |
| ISSN: | 1938-2723 |
| Popis: | Sickle cell disease (SCD) is a genetically inherited hemolytic anemia increasingly appreciated as a chronic inflammatory condition and hypercoagulable state with high thrombotic risk. It is associated with disturbed immune phenotype and function and circulating microparticles (MPs) derived from multiple cell sources. This study was carried out to determine MPs profiles in patients with sickle cell anemia (either on hydroxyurea (HU) therapy or those with no disease-modifying therapy) and to compare these profiles with healthy children. Moreover, our study assesses the potential impact of HU on other aspects of circulating MPs. We performed a cross-sectional study on 30 pediatric patients with SCD divided by treatment into 2 groups (those receiving HU or no therapy) attending Hematology Clinic and 20 age-matched healthy children. The blood samples obtained were analyzed for MPs by flow cytometry. Sickle cell disease group with no therapy showed elevated levels of total, platelet, and erythroid MPs. In contrast, therapy with HU was associated with normalization of MPs. This study provided additional evidence that HU is an effective treatment option in pediatric patients with SCD, as it seems that it decreases the abnormally elevated MPs in those patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|